Table 1.

Patient characteristics

Patient no.	WHO subtype	Clonal chromosomal abnormalities detected	IPSS‐R Risk group	CD34+CD38−CLEC12A+/ CD34+CD38−	AML‐free survival (d)
1	RAEB‐1	No aberrations	LOW	0%
2	RAEB‐1	No aberrations	INT	0%	605
3	RCMD	No aberrations	V‐LOW	0%
4	RCUD	+8	LOW	37·9%	1169
5	RAEB‐1	inv(3)(p12q26)	V‐HIGH	6·3%	583
6	RAEB‐1	No aberrations	INT	56·7%	16
7	RCUD	Complex	INT	0%
8	RAEB‐1	+del(1)(p13), +8	INT	1·5%	658
9	RCUD	No aberrations	V‐LOW	17·4%	154
10	NAa	ND	NA	1·8%	713
11	Hypo RCUD	No aberrations	LOW	4·1%	91
12	RAEB‐1	No aberrations	HIGH	0%
13	RAEB‐1	No aberrations	INT	6·4%
14	RCUD	‐X	INT	22·6%
15	RCUD	No aberrations	LOW	11·6%
16	RCUD	No aberrations	V‐LOW	14·7%
17	RARS	No aberrations	LOW	0%
18	MDS‐U	No aberrations	LOW	3·2%	210
19	RAEB‐2	No aberrations	HIGH	4·3%
20	RCUD	del(15)(q22q26)	HIGH	5·6%
21	RAEB‐2	Complex, incl. del(5q)(q13q33),‐7	V‐HIGH	0·6%	55
22	RCUD	‐7	INT	5·6%
23	RCUD	No aberrations	LOW	1·2%
24	RCUD	No aberrations	V‐LOW	6·8%	405
25	MDS‐U	+mar	LOW	0%	670
26	RCUD	No aberrations	INT	0%	554
27	RCUD	‐Y	V‐LOW	0%
28	RCUD	No aberrations	V‐LOW	7·4%
29	RCUD	+8	INT	12·0%	482
30	RCMD	Complex, incl. ‐5, ‐7	NAa	17·4%
31	Del(5q)	del(5)(q13q31)	INT	0·1%

AML, acute myeloid leukaemia; INT, intermediate; IPSS‐R, Revised International Prognostic Scoring System; MDS‐U, myelodysplastic syndrome – unclassified; NA, not applicable; ND, not done; RAEB‐1, refractory anaemia with excess blasts type 1; RAEB‐2, refractory anaemia with excess blasts type 2; RARS, refractory anaemia with ringed sideroblasts; RCMD, refractory cytopenia with multilineage dysplasia; RCUD, refractory cytopenia with unilineage dysplasia; V‐HIGH, Very High; V‐LOW, Very Low; WHO, World Health Organization.

^aInsufficient material for complete morphological evaluation.